Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Recurrence × Gadolinium × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Brain Neoplasms 4 Glioma 2 Central Nervous System Neoplasms 2 Subclinical Breast Cancer Lesion 1 Recurrence 1 Prostatic Neoplasms 1 Neoplasm Recurrence, Local 1 Liver Neoplasms 1 Head and Neck Neoplasms 1 Glioblastoma 1 Diffuse Intrinsic Pontine Glioma 1 Cranial Nerve Diseases 1 Childhood Brain Neoplasm 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Intraductal, Noninfiltrating 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Brain Tumor Adult 1 Adult Brain Glioblastoma 1

Interventions

Cyclophosphamide 101 Dexamethasone 56 Cytarabine 47 fludarabine phosphate 45 fludarabine 44 Rituximab 44 Gemcitabine 34 Lenalidomide 33 Peripheral Blood Stem Cell Transplantation 32 Etoposide 32 pembrolizumab 30 Radiotherapy 29 Filgrastim 29 Busulfan 28 Cyclosporine 26 Methotrexate 25 Melphalan 25 Carboplatin 25 Cisplatin 24 venetoclax 23 Mycophenolic Acid 23 Paclitaxel 22 Bortezomib 22 Whole-Body Irradiation 21 Granulocyte Colony-Stimulating Factor 20 Bevacizumab 20 Antilymphocyte Serum 19 Temozolomide 18 Oxaliplatin 17 Decitabine 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03154996 2022-07-05

Chronic Convection Enhanced Delivery of Topotecan

Columbia University

Phase 1 Completed

Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡